News and Announcements
Read the latest news from the Division of Hematology/Oncology including awards, publications and announcements.
The Northwestern University Clinical and Translational Sciences (NUCATS) Institute hosted the first virtual COVID-19 symposium, which gave the Northwestern research community an opportunity to learn about efforts to advance public health and respond to the COVID-19 pandemic.
A brief course of immunotherapy resulted in complete and near complete remission in nearly two-thirds of previously untreated patients with classical Hodgkin lymphoma, according to a Northwestern Medicine trial.
A new immunotherapy treatment for recurrent B-cell lymphoma was found to be safe in a trial of nearly 350 patients, according to a study published in The Lancet.
Men with advanced prostate cancer who were treated based on the genetic makeup of their cancer survived significantly longer than those treated with standard treatments, according to a new study.
Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.
Certain factors are associated with increased risk of death in critically ill COVID-19 patients, according to recent Northwestern Medicine studies.
Cancer patients with other comorbidities have a higher risk of dying from complications due to COVID-19, and should discuss the risks and benefits of continuing cancer treatment with their physician, according to a recent study.
A novel drug called enzalutamide may extend overall survival for men with nonmetastatic, castration-resistant prostate cancer, according to findings from clinical trial published in The New England Journal of Medicine.
Northwestern Medicine scientists have discovered an alternate mechanism for aberrant gene splicing that contributes to T-cell lymphoblastic leukemia, according to a recent study.
Mutations in the genes RAS and RAF allow cancer cells to create their own nucleotides, fueling cancer growth, according to a recent study published in Molecular Cell.
A new Northwestern Medicine study found important differences in rare skin lymphomas stemming from their specific cell of origin and clinical presentations, according to findings published in Nature Communications.
A new Northwestern Medicine study discovered a new and unexpected function for the transcriptional regulator MLL2/COMPASS.
For the first time, advanced prostate cancer has been treated based on the genomic makeup of the cancer, delaying disease progression for patients with a treatment-resistant form of prostate cancer.
A novel drug called luspatercept may reduce blood transfusion burden for patients with transfusion-dependent beta-thalassemia, an inherited blood disorder.
A new study has found that genetic alterations in a rare form of leukemia physically change the architecture of DNA, fueling the replication and spread of cancer cells.
A specialized subset of rare immune cells called plasmacytoid dendritic cells may promote antitumor immunity, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.
Northwestern University scientists received top honors from the Clinical Research Forum as part of its 2020 Top Ten Clinical Research Achievement Awards program, taking home the association’s highest honor and capturing more finalist nominations than any other institution.
Nanoparticles traveled to different organs in the body depending on the type of protein coating applied, according to a recent study.
Risk of relapse for chronic myeloid leukemia patients may be reduced through drug combination after discontinuing initial therapy, according to a Northwestern Medicine study published in the journal Leukemia.
Using mathematical modeling and optical imaging they developed themselves, a Northwestern University research team has discovered how chromatin folds at the single-cell level.
A new Northwestern University study has discovered that the packing of the three-dimensional genome structure, called chromatin, controls how cells respond to stress.
A new review has found that a combination of endocrine inhibitors and hormone therapy is more effective in prolonging progression-free survival for advanced breast cancer patients, as compared to chemotherapy.
The first prostate cancer treatment based on the genetic makeup of the cancer resulted in significant improvements, according to a large international trial led by Northwestern Medicine investigators.
Students, faculty and staff gathered to celebrate the Driskill Graduate Program in Life Sciences, welcoming new students and recognizing distinguished upperclassmen and graduates.
The safety of a new therapy for an aggressive brain tumor was demonstrated in a recent clinical trial, and the drug also cleared other important hurdles.
Sheetal Kircher, MD, ’11 GME, is laser-focused on cancer drug distribution and pricing: she spent a year as a health policy fellow at the ASCO and published a paper on the topic in JAMA.
An emerging class of cancer drugs has shown promise in treating pancreatic cancer, but the drugs may cause severe liver damage when combined with high-fat diets, according to study published in PNAS.
In a surprising new finding, radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer following surgery.
A combination of idelalisib and rituximab is an effective and safe treatment for patients with relapsed chronic lymphocytic leukemia, according to the results of a phase III clinical trial.
A drug called regorafenib significantly improved progression-free survival in patients with metastatic osteosarcoma, according to a study published in the Journal of Clinical Oncology.